WVE - Wave Life Sciences Ltd.
| Previous Close | 26.70 |
| Open | 26.46 |
| Bid | 28.16 x 800 |
| Ask | 28.24 x 800 |
| Day's Range | 26.12 - 28.55 |
| 52 Week Range | 22.90 - 56.00 |
| Volume | 267,214 |
| Avg. Volume | 513,343 |
| Market Cap | 961.824M |
| Beta (3Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.06 |
| Earnings Date | Aug 14, 2017 - Aug 18, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 56.14 |
- Simply Wall St.•2 days ago
What Are Analysts Saying About Wave Life Sciences Ltd.'s (NASDAQ:WVE) Earnings Trajectory?
Wave Life Sciences Ltd.'s (NASDAQ:WVE) latest earnings announcement in December 2018 indicated that losses became smaller relative to the prior year's level - great news for investors...
- Zacks•8 days ago
Wave Life Sciences Plunges After DMD Study Data Readout
Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
- Benzinga•8 days ago
The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 16) Eidos Therapeutics Inc (NASDAQ: EIDX )(reported fourth ...
- Associated Press•9 days ago
Qualcomm and Progressive jump while Wave Life Sciences drops
Stocks that moved substantially or traded heavily on Tuesday: Qualcomm Corp., up $13.27 to $70.45 The mobile chip maker settled a long-running financial dispute with iPhone maker Apple. Johnson & Johnson, ...
- Benzinga•9 days ago
Why Wave Life Sciences's Valuation Is Falling By 25%
Small-cap biotech Wave Life Sciences Ltd (NASDAQ: WVE ) — which fell last week following a delay in the release of top-line data from its Huntington disease candidates — is once again under pressure ...
- GlobeNewswire•9 days ago
Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design
Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the final results from its Phase 1 clinical trial of investigational suvodirsen (WVE-210201) in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. The company also announced the design of its planned Phase 2/3 clinical trial of suvodirsen in DMD, DYSTANCE 51.
- Benzinga•12 days ago
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...
- GlobeNewswire•13 days ago
Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference
Suvodirsen Phase 1 Safety and Tolerability Results Accepted for Oral Presentation Investor Conference Call and Webcast Scheduled for Tuesday, April 16 CAMBRIDGE, Mass., April.
- TheStreet.com•15 days ago
Wave Life Sciences Plunges on Clinical Trial Data Delay
shares were down more than 16% to $34.85 Wednesday after the biopharmaceutical company said it will delay the release of top-line data from the clinical trials of its Huntington's disease treatment candidate. "When we initiated these exciting clinical trials to explore the potential of an allele-selective approach to treating Huntington's disease, we set aggressive timelines for ourselves in recognition of the enormous need in the global Huntington's disease community. While we are disappointed that enrollment is not as fast as we anticipated, we are pleased that patient and physician interest in the trials remains high," said Dr. Michael Panzara, chief medical officer at Wave Life Sciences.
- GlobeNewswire•15 days ago
Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs
Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today provided an update on the timing of the topline data readout from its ongoing PRECISION-HD program, which consists of two global Phase 1b/2a clinical trials evaluating investigational therapies WVE-120101 and WVE-120102 for patients with Huntington’s disease (HD). The company now expects to report topline clinical data from the PRECISION-HD program by the end of the year. This update is not due to a preclinical or clinical safety finding and the PRECISION-HD clinical program remains blinded.
- American City Business Journals•28 days ago
Sarepta plans second Duchenne drug application this year
With one drug already being considered by the FDA, Sarepta Therapeutics Inc. is now planning to submit another drug for Duchenne muscular dystrophy to the FDA this year.
- GlobeNewswire•last month
Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference
Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that four poster presentations highlighting new data and progress for its Duchenne muscular dystrophy (DMD) programs will be shared at the 2019 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference themed, “Progress in Motion,” April 13-17, 2019 in Orlando, Fla. This year the MDA annual conference will gather both healthcare providers and researchers together into one conference to discuss the latest in neuromuscular disease research and care.
- Simply Wall St.•2 months ago
Should You Be Worried About Insider Transactions At Wave Life Sciences Ltd. (NASDAQ:WVE)?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
- GlobeNewswire•2 months ago
Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference
CAMBRIDGE, Mass., March 06, 2019 -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for.
- GlobeNewswire•2 months ago
Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update
CAMBRIDGE, Mass., March 01, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•2 months ago
Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs ...
- Simply Wall St.•3 months ago
Why Wave Life Sciences Ltd.’s (NASDAQ:WVE) CEO Pay Matters To You
Paul Bolno has been the CEO of Wave Life Sciences Ltd. (NASDAQ:WVE) since 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies Read More...
- American City Business Journals•3 months ago
New life science internship program launches to help boost diversity
In the inaugural year of Project Onramp, 50 low-income students will be placed in paid science, engineering, communication, marketing and other internships with local biotech and medical device companies, according to the announcement made Tuesday.
- Motley Fool•3 months ago
Here's Why Wave Life Sciences Is Crashing Today
Investors aren't too thrilled about this biotech's latest share offering.
- GlobeNewswire•3 months ago
Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares
Wave Life Sciences Ltd. (WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten public offering of 3,950,000 of its ordinary shares at a price to the public of $38.00 per ordinary share. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 592,500 of its ordinary shares on the same terms and conditions.
- GlobeNewswire•3 months ago
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares
Wave Life Sciences Ltd. (WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of its ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in the public offering on the same terms and conditions. All of the shares in the offering will be sold by Wave Life Sciences.
- American City Business Journals•3 months ago
FDA pilot program could help Wave avoid orphan-drug pitfalls
Wave will work with FDA officials during the pilot program to design a Phase 2-3 clinical trial with a reduced number of placebo patients, tweaking standards that have stymied other rare disease products.
- Motley Fool•4 months ago
Here's Why Sarepta Therapeutics Fell 15.7% in December
A competitive threat is advancing, but investors might want to view last month's pullback as an opportunity.
- GlobeNewswire•4 months ago
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program
Wave Life Sciences Ltd. (WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the planned Phase 2/3 efficacy and safety trial for its lead Duchenne muscular dystrophy (DMD) clinical program has been selected for the U.S. Food and Drug Administration (FDA) pilot program for complex innovative trial designs (CID). The selection was based on the design of Wave’s Phase 2/3 clinical trial of suvodirsen (WVE-210201), an investigational therapy for boys with DMD who are amenable to exon 51 skipping.
